Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
GLP-1 receptor agonists are injectable treatments for type 2 diabetes and obesity, available in both daily and weekly formulations
A small pilot study in athletes found more consistent blood levels when oral doses were taken in a fasted state versus with dinner in the evening
Most clients begin with weekly injections, then adjust to a maintenance schedule under the guidance of our providers
After five weeks, the results were incredible
has happened: its pivotal Phase 3 obesity trial, TRIUMPH-1, reported topline results on May 21, 2026 (28.3% average weight loss at 80 weeks) and is now marked complete on ClinicalTrials.gov, followed by TRIUMPH-2 and TRIUMPH-3 on July 23, 2026
US$ 27.52
US$ 26.88
US$ 28.23
US$ 23.10
US$ 24.19
US$ 24.20
US$ 29.32
US$ 29.28
US$ 20.31
